Your shopping cart is currently empty

Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos/NFATc1 pathway. Latanoprost acid can be used in studies about lowering pressure inside the eyes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $52 | - | In Stock | |
| 5 mg | $148 | - | In Stock | |
| 10 mg | $238 | - | In Stock | |
| 25 mg | $477 | - | In Stock | |
| 50 mg | $708 | - | In Stock | |
| 100 mg | $972 | - | In Stock | |
| 200 mg | $1,290 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $163 | - | In Stock |
| Description | Latanoprost acid is a selective agonist of prostanoid receptors and inhibits RANKL-induced osteoclastogenesis and function through the inhibition of c-fos/NFATc1 pathway. Latanoprost acid can be used in studies about lowering pressure inside the eyes. |
| In vitro | Latanoprost acid (10, 20 μM) reduces the protein expressions of c-fos and NFATc1 thus inhibiting the mature osteoclast formation in BMMs. Latanoprost acid (10μM) and RANKL(50ng/ml) significantly inhibit ERK, p38, AKT and JNK[1]. |
| In vivo | Latanoprost acid (i.p.; 20 mg/kg; once daily for 7 days) effectively prevents LPS-induced bone destruction [1]. |
| Molecular Weight | 390.51 |
| Formula | C23H34O5 |
| Cas No. | 41639-83-2 |
| Smiles | O[C@H](CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O)CCc1ccccc1 |
| Relative Density. | 1.159 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (70.42 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.12 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.